The Oncology Institute Names Minh Merchant Chief Legal Officer
Rhea-AI Summary
The Oncology Institute (NASDAQ: TOI) appointed Minh Merchant as Chief Legal Officer effective April 6, 2026. Ms. Merchant will oversee legal, regulatory, compliance and privacy functions to support TOI's scaling as a national oncology platform.
She brings more than two decades of healthcare legal experience, prior general counsel roles at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and a JD from UCLA School of Law.
Positive
- Chief Legal Officer hire adds experienced legal leadership
- 20+ years of healthcare transactional and regulatory experience
- Prior GC roles at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson
- Mandate covers legal, regulatory, compliance and privacy functions
Negative
- None.
News Market Reaction – TOIIW
In the Apr 6 session, TOIIW gained 15.83%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Earnings and guidance | Positive | +107.7% | Strong 2025 revenue growth and detailed 2026 guidance including EBITDA outlook. |
| Feb 26 | Earnings call date | Neutral | +12.4% | Announcement of Q4 and full-year 2025 earnings release timing and conference call. |
| Feb 25 | Investor conferences | Positive | +6.4% | Participation in three March investor conferences to increase visibility with investors. |
| Feb 23 | Board appointment | Positive | +0.0% | Appointment of experienced healthcare executive Kim Tzoumakas to Board of Directors. |
| Jan 12 | Guidance reaffirmed | Positive | -5.6% | Reaffirmed 2025 guidance and outlined 2026–2028 growth, margin, and mix targets. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Shares have reacted strongly to growth and earnings-related updates, while governance and guidance news have produced mixed or muted moves.
Over recent months, The Oncology Institute highlighted strong growth, with Q4 2025 revenue of $142.0M and full-year 2025 revenue of $502.7M, plus 2026 revenue guidance of $630–650M. It reaffirmed guidance and a longer-term growth outlook on Jan 12, 2026, and later reported detailed 2025 results on Mar 12, 2026 with a sharp positive price reaction. The company also increased investor engagement via multiple conferences and refreshed governance with a new board member, providing context for today’s additional leadership appointment in the legal function.
Key Terms
value-based oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors.
Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant experience in transactional, regulatory and compliance matters. She previously served as general counsel at Midi Health, Kyverna Therapeutics, Aspira Women’s Health and McKesson, and holds a JD from UCLA School of Law.
“We are excited to welcome Minh to TOI as our Chief Legal Officer,” said Daniel Virnich, MD, CEO of The Oncology Institute. “As our footprint and care model continue to grow, she brings the depth of experience to help TOI continue operate as a compliant and secure national oncology platform.”
“I’m thrilled at the opportunity to join TOI at this important juncture in the organization’s growth as a public company,” commented Ms. Merchant. “The organization’s mission to provide better access and affordability to cancer care is inspiring and I feel that I’m well positioned to help TOI continue its successful navigation of the rapidly evolving healthcare legal and regulatory environment.”
About The Oncology Institute (www.theoncologyinstitute.com):
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.
Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com
Investors
ICR Healthcare
TOI@icrhealthcare.com
